drugset
drugset / Trial / NCT02030405

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02030405 ↗

Phase 2 Terminated 4 enrolled Steven E. Coutre National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase 2 trial studies how well ixazomib(MLN9708) works in treating study participants with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2014-03
Primary completion
2015-11
Completion
2015-11

Outcome

Outcome not reported

Stopped: “Regulatory”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown — Oral

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myelomonocytic leukemia M4 adult acute monocytic leukemia